Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013–2014 malaria season

Malaria Journal

Research

Boubacar Wade¹  Bécaye Fall²  Yaya Diemé²  Bruno Pradines³  Pierre Dionne⁴  Aminata Nakoulima⁵  Bakary Diatta⁶  Mansour Fall⁶  Cheikhou Camara⁷ 

[1] Chefferie, Hôpital Principal de Dakar, Dakar, Sénégal;Laboratoire d’étude de la chimiosensibilité du paludisme, Fédération des laboratoires, Hôpital Principal de Dakar, Dakar, Sénégal;Laboratoire d’étude de la chimiosensibilité du paludisme, Fédération des laboratoires, Hôpital Principal de Dakar, Dakar, Sénégal;Unité de Parasitologie et d’Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France;Aix Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Marseille, France;Centre National de Référence du Paludisme, Marseille, France;Maternité Hôpital Principal de Dakar, Dakar, Sénégal;Service de Pédiatrie, Hôpital Principal de Dakar, Dakar, Sénégal;Service de Réanimation Médicale, Hôpital Principal de Dakar, Dakar, Sénégal;Service des Urgences, Hôpital Principal de Dakar, Dakar, Sénégal;

关键词: Malaria;    Plasmodium falciparum;    Anti-malarial;    In vitro;    Resistance;    Senegal;    Proveblue;    Methylene blue;   

DOI  :  10.1186/s12936-015-0589-3

 received in 2014-10-09, accepted in 2015-01-27,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundIn 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. Since the introduction of ACT, there have been very few reports on the level of Plasmodium falciparum resistance to anti-malarial drugs. An ex vivo susceptibility study was conducted on local isolates obtained from the Hôpital Principal de Dakar (Dakar, Senegal) from November 2013 to January 2014.MethodsEighteen P. falciparum isolates were sussessfully assessed for ex vivo susceptibility to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (MDAQ), the active metabolite of amodiaquine, mefloquine (MQ), lumefantrine (LMF), artesunate (AS), dihydroartemisinin (DHA), the active metabolite of artemisinin derivatives, pyronaridine (PND), piperaquine (PPQ), and, Proveblue (PVB), a methylene blue preparation, using the HRP2-based ELISA test.ResultsThe prevalence of isolates with reduced susceptibility was 55.6% for MQ, 50% for CQ, 5.6% for QN and MDAQ, and 0% for DHA, AS and LMF. The mean IC50 for PND, PPQ and PVB were 5.8 nM, 32.2 nM and 5.3 nM, respectively.ConclusionsThe prevalence of isolates with a reduced susceptibility to MQ remains high and stable in Dakar. Since 2004, the prevalence of CQ resistance decreased, but rebounded in 2013 in Dakar. PND, PPQ and PVB showed high in vitro activity in P. falciparum parasites from Dakar.

【 授权许可】

Unknown   
© Fall et al.; licensee BioMed Central. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.